The $10B TAVR Market Grew. Why Are Most Patients Still Untreated?

Anteris says only ~20% of U.S. aortic stenosis patients receive treatment despite a ~$10B TAVR market, pushing a “category reset” built on outcomes rather than delivery performance. The company’s PARADIGM trial will head-to-head test DurAVR® THV versus commercially available TAVR devices, aligning with concerns that long-term durability beyond 10 years remains unknown as TAVR expands to younger patients. Supporting context: prior Evolut low-risk data showed higher repeat valve interventions at 6 years (5.5% TAVR vs 3.3% surgery) and in 7-year data (9.8% vs 6%), while clinician electronic notifications increased valve interventions by 40% and heart-team evaluations by 27% within 90 days.

Analysis

This reads more like a category-expansion narrative than a near-term earnings event. The real economic lever is not a single device launch; it is whether improved detection and referral convert a large pool of untreated patients into procedures over 6-18 months. That primarily benefits the incumbent high-volume structural heart franchises first, because they already own physician workflows, service contracts, and reimbursement muscle; a small entrant still has to prove manufacturability, hospital economics, and durable outcomes before it can take share.

The second-order risk for the incumbents is a higher clinical bar. If head-to-head data begins rewarding hemodynamics/durability over procedural ease, the market may start valuing TAVR less like an engineering adoption story and more like a chronic-disease platform with replacement-cycle economics. That is constructive for procedure growth, but potentially negative for device mix and pricing if buyers demand better outcomes without paying materially more. The likely losers are low-differentiation valve vendors and any OEMs reliant on “good enough” next-gen iterations.

Near term, the tradeable catalyst is referral volume, not trial rhetoric: if clinician-alert tools truly raise intervention rates, that should show up first in cath lab utilization and hospital procedure counts within 1-3 quarters. The contrarian miss is that underdiagnosis may be the bigger bottleneck than device superiority, meaning the market could be overestimating how much share a new valve can win before the funnel itself expands. What would falsify the constructive structural-heart view is a lack of procedure acceleration by the next two quarterly updates, or any signal that durability concerns are reducing TAVR adoption in younger patients rather than broadening it.

Key Decisions for Investors

• Long MDT on a 3-6 month horizon as a beneficiary of a larger diagnosed/referral funnel; thesis works if procedure volumes and structural-heart commentary improve, but fades if incremental interventions fail to accelerate.
• Avoid chasing HRTT/INSO into the release; this is still a clinical-validation story, not a revenue inflection. Reassess only after PARADIGM comparative data or commercial path clarity.
• Pair trade: long MDT / short a basket of smaller speculative TAVR developers for 6-12 months. The market tends to reward proven distribution and reimbursement over platform claims until randomized data is de-risked.
• Set an alert for any 1-3 quarter uptick in TAVR volume or referral metrics at major hospital systems; that is the first real monetization signal and the earliest place to add exposure.
• If PARADIGM shows meaningfully lower gradients but no safety or durability edge, fade the multiple expansion trade in the entrant and keep the bullish view confined to incumbents.